Ajinomoto Co., Ltd.

Other

Kazuo Sugamura

Mitsui Chemicals, Inc.

Junji Hamuro

Toshiro Shimamura

Toshikazu Takeshita

Manabu Suzuki

Masataka Nakamura

Hironobu Asao

Harumi Nakazawa

Yuka Kanayama

Norikazu Higashimura

Kazuko Murata

The present invention relates to a pharmaceutical composition for the therapeutic treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, sarcoidosis, autoimmune uveitis, and inflammatory bowel disease, or graft-versus-host disease. The pharmaceutical composition contains, as the effective ingredient, a gp34 binding-inhibitory substance.

Medicinal composition containing gp34 binding-inhibitor as the active ingredient

The present invention relates to an IL-2 receptor .gamma. chain molecule, a DNA-sequence encoding the IL-2 receptor .gamma. chain molecule, a vector possessing said DNA-sequence, a cell transformed with said vector, a method for the production of an IL-2 receptor .gamma. chain molecule by culturing of said cell, an immune response regulatory agent comprising an IL-2 receptor .gamma. chain molecule and an antibody to an IL-2 receptor .gamma. chain molecule.

Human IL-2 receptor .gamma.-chain molecule antibody

A polypeptide which specifically binds to the .gamma.-chain of the human interleukin-2 receptor and selectively inhibits the binding of the .gamma.-chain of human interleukin-2 receptor to the .beta.-chain of the same is provided. The polypeptide has an activity of blocking the human interleukin-2 response. Also provided are an immunosuppressant containing the polypeptide, a DNA gene coding for the polypeptide, a recombinant DNA having the gene, a transformant having the recombinant DNA, and a method for producing the intended polypeptide by incubating the transformant. The novel polypeptide can be used independently, or with substances capable of inhibiting the binding of interleukin-2 to the interleukin-2 receptor, as a medicine for preventing the rejection of grafts after transplantation and also for curing inflammatory diseases such as allergic diseases and autoimmune diseases.

.gamma.-chain humaninterleukin-2 receptor polypeptide and method of

The invention provides a method for detecting (1) leukemia, (2) cancer, (3) autoimmune disorder, (4) inflammatory disorder, (5) allergic disorder or (6) viral infection, characterized by measuring soluble, human interleukin-2 receptor .gamma.-chain molecules existing in a human body fluid by an immunochemical method using an antibody/antibodies specifically reacting with human interleukin-2 receptor .gamma.-chain molecule, and a reagent for the detection.

Method and reagent detecting human disorders

The present invention relates to an IL-2 receptor .gamma. chain molecule, a DNA-sequence encoding the IL-2 receptor .gamma. chain molecule, a vector possessing said DNA-sequence, a cell transformed with said vector, a method for the production of an IL-2 receptor .gamma. chain molecule by culturing of said cell, an immune response regulatory agent comprising an Il-2 receptor .gamma. chain molecule and an antibody to an IL-2 receptor .gamma. chain molecule. Both the Il-2 receptor .gamma. chain molecule and the antibody to the IL-2 receptor .gamma. chain molecule are very useful immune response regulatory agents.

Human IL-2 receptor .gamma. chain molecule

Monoclonal antibodies which bind the gamma chain of human interleukin-2

Growing community of inventors

Sendai, Japan

Kazuo Sugamura